An investigation on behalf of investors of Novavax, Inc. (NASDAQ:NVAX) shares over potential securities laws violations by Novavax, Inc. and certain of its directors and officers in connection with certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Novavax, Inc. (NASDAQ:NVAX) concerning whether a series of statements by Novavax, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Gaithersburg, MD based Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants.
Novavax, Inc. reported that its annual Total Revenue declined from $36.25 million in 2015 to $15.35 million in 2016 and that its Net Loss increased from $156.94 million in 2015 to $279.97 million in 2016.

In November 2017, Novavax, Inc. projected a year-end release for top-line data from the Company's Phase 1/2 clinical trial of its NanoFlu Vaccine.

Then, on December 19, 2017, Novavax, Inc. announced that a 'complete package' will not be completed and released until February 2018. Novavax, Inc. advised investors that 'the wild-type viruses necessary to assess immunogenicity of the vaccines to circulating strains have been difficult to obtain, grow and maintain genetic stability.'